The caveat at the moment is that the evidence is still highly preliminary. Now that doesn’t mean it might not pan out and provide another good option in the treatment toolkit down the road a bit further, and the nature of the drug ... if it truly can lessen ventricular impact ... makes it worth investigating for sure, but I caution anyone that is ready to proclaim it the next second coming to hold their water for a good while longer until it passes solid multiple replications of phase 3 trials before heralding a new step forward in anti-arrhythmic drugs.
Mark it under interesting, but as yet no cigar to write home about! The vast majority of highly touted Phase 1 studies that earn early marketing hype never make it past phase three and into the marketplace.
Shannon